ReviewJournal of gastroenterology2009
New therapeutic approaches to hepatitis C virus.
Review in Journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 35 citations in OpenAlex.
- Hepatitis C virus-induced prion protein expression facilitates hepatitis C virus replication.Virologica Sinica · 2017Article
- The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients.Hepatitis monthly · 2016Article
- Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions.Journal of immunology research · 2015Article
- UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication.Bioorganic & medicinal chemistry letters · 2014Article
- Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein.Antimicrobial agents and chemotherapy · 2013Article
- Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.Hepatology international · 2013Article
- Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.Antimicrobial agents and chemotherapy · 2011Article
- Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase.The Journal of general virology · 2011Article
- Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase.Antimicrobial agents and chemotherapy · 2010Article
- Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.Journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Year 201X will see a huge battle against hepatitis C virus (HCV) infection. HCV, a leading cause of end stage diseases and hepatocellular malignancies, is a negative legacy of the past in many regions worldwide, and has long been refractory to conventional treatments. The most effective peginterferons and ribavirin-based antiviral therapies can eliminate the virus in only half of patients treated, and the treatments are often poorly tolerated. Recently, the development of an HCV cell culture system has become a turning point of basic research. At present, novel therapeutic agents with different mechanisms of action are under development or on clinical trials. Some of these drugs have been proven to be effective when used with the conventional treatments, and may constitute antiviral therapies without being used in combination with interferons. This article reviews the current status of preclinical drug development, ongoing clinical trials, and near future perspectives in the field of HCV therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.